Favipiravir is an antiviral developed against influenza, a different virus. It is approved for influenza in Japan. It is being tested in a Chinese trial and showed some efficacy against COVID-19 (https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en). However, those data are not accessible, so it is hard to tell how beneficial it is. Another source of information about antiviral agents is https://drugvirus.info/